Retatrutide 20mg: research supplier availability in the EU
Comparing 20mg · Vial. Different forms are not interchangeable.
Retatrutide 20mg is not sold as a Vial by any EU vendor we track; switch form or size to see prices.
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence. Read identity checks and sources ↓ · Research guides ↓
- Category
- Selected package
- Sizes
- Vendors
- Form at this size
- Use
No EU vendor we track stocks Retatrutide 20mg right now. Other forms and sizes are compared above. Check each offer’s source date.
Retatrutide 20mg Vial prices by vendor
Where to buy Retatrutide in other markets
Prices below are collected in each vendor’s original currency. Compare matching sizes and forms within one market. Shipping, taxes and unconfirmed coupon discounts are excluded; check the vendor’s destination policy before ordering.
United Kingdom · GBP prices and supplier coverage →
| Vendor | Size / form | Price | Stock | Source checked |
|---|---|---|---|---|
| AllMyPeptides View product ↗ | 10mg · Vial | £42.99 | In stock | 2026-09-17 |
| AllMyPeptides View product ↗ | 20mg · Vial | £72.99 | In stock | 2026-09-17 |
| AllMyPeptides View product ↗ | 30mg · Vial | £92.99 | In stock | 2026-09-17 |
| AllMyPeptides View product ↗ | 40mg · Vial | £119.45 | In stock | 2026-09-17 |
| AllMyPeptides View product ↗ | 60mg · Vial | £169.99 | In stock | 2026-09-17 |
Canada · CAD prices and supplier coverage →
| Vendor | Size / form | Price | Stock | Source checked |
|---|---|---|---|---|
| Nuvion Peptides View product ↗ | 10mg · Vial | CA$99.99 | In stock | 2026-09-18 |
| Nuvion Peptides View product ↗ | 30mg · Vial | CA$189.99 | In stock | 2026-09-18 |
Australia · AUD prices and supplier coverage →
| Vendor | Size / form | Price | Stock | Source checked |
|---|---|---|---|---|
| PhaseOne View product ↗ | 5mg · Vial | A$76.99 | In stock | 2026-09-18 |
| PhaseOne View product ↗ | 10mg · Vial | A$119.99 | In stock | 2026-09-18 |
| PhaseOne View product ↗ | 15mg · Vial | A$167.99 | In stock | 2026-09-18 |
| PhaseOne View product ↗ | 20mg · Vial | A$207.99 | In stock | 2026-09-18 |
| PhaseOne View product ↗ | 30mg · Vial | A$247.99 | In stock | 2026-09-18 |
| PhaseOne View product ↗ | 60mg · Vial | A$329.99 | In stock | 2026-09-18 |
Retatrutide for sale: price by size
Where to buy Retatrutide
Particle Peptides lists Retatrutide. Package sizes: 10mg. Lowest recorded in-stock offer: €149.99 for 10mg Vial. COA availability is vendor-reported. Shipping coverage: EU-wide from Slovakia · no Schengen customs. Payment methods: Card, Bank transfer.
Retatrutide suppliers compared
Certificate availability is vendor-reported. Check the exact product and batch document; PeptideTech has not authenticated the sample.
Source, shipping and code status →Research reference
Selected sources reviewed
Retatrutide, also identified as LY3437943, is an investigational agonist at GIP, GLP-1 and glucagon receptors. A peer-reviewed phase 2 trial and a later sponsor-described phase 3 program are different levels of source evidence.[1][2]
Identity checks
“Triple agonist” names the three receptor targets; it does not identify a separate “GLP-3” receptor or authenticate a product sold under that nickname.[1][2]
Published phase 2 evidence; phase 3 sponsor updates
The published randomized phase 2 trial enrolled 338 adults. Lilly’s current information describes an investigational phase 3 development program. Sponsor updates are identified as sponsor information, not substituted for a peer-reviewed paper or regulatory approval.[1][2]
Regulatory context
FDA states that retatrutide is not a component of an FDA-approved drug. Lilly describes it as investigational. This review does not infer regulatory status for every country.[3][2]
Supporting sources
- Retatrutide for obesity: a randomized phase 2 trialNew England Journal of Medicine · PubMed record · checked
- What to know about retatrutideEli Lilly and Company · trial sponsor · checked
- FDA concerns with unapproved GLP-1 drugs used for weight lossU.S. Food and Drug Administration · checked
Research searches — not supporting citations
Search results may include unrelated records. A search link does not establish that a matching study exists.
These selected sources describe named substances and studied formulations. They do not authenticate a supplier, a certificate of analysis or the contents of a particular lot, and do not provide instructions for use. “Healing” and other catalogue categories are navigation labels, not evidence of efficacy or treatment recommendations.
Retatrutide research and reading
Read the evidence, identity checks and limitations alongside the catalogue. Research findings do not verify a vendor’s product or establish suitability for personal use.
Retatrutide vs tirzepatide vs semaglutide: mechanisms and evidence
Compare receptor targets, regulatory context and the studies that can—and cannot—support a fair comparison of these three molecules.
Updated Sep 17, 2026Retatrutide: what the research shows and its approval status in 2026
A dated guide to retatrutide’s three receptor targets, peer-reviewed results, newer trial announcements and the limits of current evidence.
Updated Sep 17, 2026Retatrutide research listings: names, formats and price checks
Understand retatrutide catalogue names and compare research listings by product identity, form, size, source date and vendor-specific coupon status.
Updated Sep 17, 2026Retatrutide price history
Actual source observations from the last 14 days, shown separately by supplier, package and currency. Missing days are not filled in. The first refresh can preserve an earlier recorded price; it does not establish a daily price history.
No observation history has been recorded for this selection yet. Current offer dates are shown in the price table.
Save Retatrutide
Bookmark this product in your browser. To keep a particular supplier, size and form, use “Save offer” beside a price. Neither feature sends alerts or creates a subscription.
Is Retatrutide legal? Research-use status
This page compares research-labelled listings for Retatrutide. A listing or a European Union price does not establish authorization for human use or permission to import, possess or supply a product in a particular jurisdiction. Consult the cited regulatory sources and the rules for the actual product and destination. PeptideTech does not sell products or provide medical advice.
FDA states that retatrutide is not a component of an FDA-approved drug. Lilly describes it as investigational. This review does not infer regulatory status for every country.
Retatrutide storage and handling (research context)
Follow the manufacturer’s current product- and batch-specific storage instructions and safety data sheet for Retatrutide. The catalogue does not verify temperature stability, sterility or a preparation method. Do not transfer handling instructions between different forms, concentrations or suppliers.
Retatrutide price: questions
Automated price sources are scheduled daily; other sources are checked manually. Check the offer's last successful source timestamp. A code is shown when it is attached to an offer or affiliate link. The displayed price includes a discount only when that code is cart-verified and the discounted price is explicitly recorded; otherwise it is the vendor's listed price. Prices exclude shipping. Stock status is captured at the same time. Rankings are by displayed price only. PeptideTech earns a commission when you buy through a link; it never changes the order.
Full method →Compare Retatrutide with other research products
Compare package prices and forms; distinct compounds are not interchangeable.
Retatrutide vs Tirzepatide: prices and packagesAll research product comparisons